title: Does the emergence and persistence of donor-derived leukaemia-reactive cytotoxic T lymphocytes protect patients given an allogeneic BMT from recurrence? Results of a preliminary study.
abstract: The frequency of CTL precursors (CTLp) directed towards recipient-derived pre-transplant leukaemic blasts (LB) was measured in the peripheral blood of nine children with acute leukaemia and given BMT from either an HLA-identical sibling or a matched unrelated donor (MUD). Patients were evaluated at various time points between 1 month and more than 2 years after transplantation. A high frequency of donor-derived LB-reactive CTLp was detectable 2-6 months after BMT in all children and persisted for at least up to 18 months in the eight patients in haematological remission, while it rapidly declined in the only patient who relapsed. Generation of LB-reactive T cell clones obtained from some of these patients demonstrates that various T lymphocyte subsets, either HLA class I-restricted/TCR-dependent or HLA-unrestricted, contribute to this phenomenon. The in vitro GVL effect here described seems to be at least partially separated from GVHR, since no correlation was observed between the emergence of LB-reactive CTLp and the development and/or severity of GVHD. Development of LB-reactive CTL in the patients was independent of the frequency of these cells in the donor. These data suggest that donor-derived CTL activity specifically directed towards leukaemic blasts may develop in patients given allogeneic BMT and contribute to the maintenance of a state of haematological remission.
authors.affiliation: Department of Pediatrics, University of Pavia, IRCCS Policlinico San Matteo, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Montagna
authors.forename: F
authors.initials: F
authors.lastname: Locatelli
authors.forename: V
authors.initials: V
authors.lastname: Calcaterra
authors.forename: P
authors.initials: P
authors.lastname: Comoli
authors.forename: A
authors.initials: A
authors.lastname: Moretta
authors.forename: G
authors.initials: G
authors.lastname: Giorgiani
authors.forename: M
authors.initials: M
authors.lastname: Zecca
authors.forename: F
authors.initials: F
authors.lastname: Bonetti
authors.forename: E
authors.initials: E
authors.lastname: Giraldi
authors.forename: G
authors.initials: G
authors.lastname: Rondini
authors.forename: R
authors.initials: R
authors.lastname: Maccario
mesh_terms: D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003602:Cytotoxicity, Immunologic; D006801:Humans; D016219:Immunotherapy, Adoptive; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000628:therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000628:therapy*; D055502:Secondary Prevention; D013602:T-Lymphocytes, Cytotoxic / Q000637:transplantation*; D014184:Transplantation, Homologous